Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1

Saadettin Kilickap, Ana Baramidze, Ahmet Sezer, Mustafa Özgüroğlu, Mahmut Gumus, Igor Bondarenko, Miranda Gogishvili, Marina Nechaeva, Michael Schenker, Irfan Cicin, Ho Gwo Fuang, Yaroslav Kulyaba, Kasimova Zyuhal, Roxana-Ioana Scheusan, Marina Chiara Garassino, Yuntong Li, Cong Zhu, Manika Kaul, Javier Perez, Frank Seebach, Israel Lowy, Jean-Francois Pouliot, Eric Kim, Heather Magnan

Open source

DOI: 10.1016/j.jtho.2025.03.033
Published: 2025-07
Container: Journal of Thoracic Oncology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.jtho.2025.03.033,
  title = {Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50\% or Higher: Five-Year Outcomes of EMPOWER-Lung 1},
  author = {Saadettin Kilickap and Ana Baramidze and Ahmet Sezer and Mustafa Özgüroğlu and Mahmut Gumus and Igor Bondarenko and Miranda Gogishvili and Marina Nechaeva and Michael Schenker and Irfan Cicin and Ho Gwo Fuang and Yaroslav Kulyaba and Kasimova Zyuhal and Roxana-Ioana Scheusan and Marina Chiara Garassino and Yuntong Li and Cong Zhu and Manika Kaul and Javier Perez and Frank Seebach and Israel Lowy and Jean-Francois Pouliot and Eric Kim and Heather Magnan},
  year = {2025},
  journal = {Journal of Thoracic Oncology},
  doi = {10.1016/j.jtho.2025.03.033},
  url = {https://doi.org/10.1016/j.jtho.2025.03.033}
}

RIS

TY  - JOUR
TI  - Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1
AU  - Saadettin Kilickap
AU  - Ana Baramidze
AU  - Ahmet Sezer
AU  - Mustafa Özgüroğlu
AU  - Mahmut Gumus
AU  - Igor Bondarenko
AU  - Miranda Gogishvili
AU  - Marina Nechaeva
AU  - Michael Schenker
AU  - Irfan Cicin
AU  - Ho Gwo Fuang
AU  - Yaroslav Kulyaba
AU  - Kasimova Zyuhal
AU  - Roxana-Ioana Scheusan
AU  - Marina Chiara Garassino
AU  - Yuntong Li
AU  - Cong Zhu
AU  - Manika Kaul
AU  - Javier Perez
AU  - Frank Seebach
AU  - Israel Lowy
AU  - Jean-Francois Pouliot
AU  - Eric Kim
AU  - Heather Magnan
PY  - 2025
JO  - Journal of Thoracic Oncology
DO  - 10.1016/j.jtho.2025.03.033
UR  - https://doi.org/10.1016/j.jtho.2025.03.033
ER  -

APA

Kilickap, S., Baramidze, A., Sezer, A., Özgüroğlu, M., Gumus, M., Bondarenko, I., Gogishvili, M., Nechaeva, M., Schenker, M., Cicin, I., Fuang, H. G., Kulyaba, Y., Zyuhal, K., Scheusan, R., Garassino, M. C., Li, Y., Zhu, C., Kaul, M., Perez, J., Seebach, F., Lowy, I., Pouliot, J., Kim, E., & Magnan, H. (2025). Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2025.03.033

Source records

crossref · retrieved 2026-09-27T01:08:45.541Z